Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Celgene and IBM to Launch Drug Safety Program



The initiative – called IBM Watson for Patient Safety – will automatically collect, organize and analyze large amounts of data generated during, and after, drug development.

Share this!

November 7, 2016 | by Sarah Hand, M.Sc.

Participation in a clinical trial testing an experimental new drug is inherently risky, despite efforts made by the study sponsor to mitigate these risks. Even a drug which has a favorable safety profile throughout the clinical trials process may be associated with some serious adverse events after the drug has been launched on the market.

To address this issue, biotechnology company, Celgene has partnered with IT giant, IBM to launch a new drug safety program. The initiative – called IBM Watson for Patient Safety – will automatically collect, organize and analyze large amounts of data generated during, and after, drug development.

Watson is IBM’s technology platform that uses machine learning to analyze vast amounts of unstructured data. In this application, Watson will pull data from a multitude of sources, including electronic medical records and medical claims databases to support pharmaceutical and biotech companies throughout their drug development processes.

“For a long time, very big decisions around the use and disposition of drugs have been taken based on small datasets,” John Freeman, Celgene’s corporate vice president of global drug safety and risk management, told FierceBiotech. “This is an opportunity to not only streamline the way that information is handled within pharma companies and regulators, but also to enable much greater clarity of insight born of an ability to access large datasets.”

The benefit to pharma companies could be the ability to access and analyze side effects information from any given drug. Patients could also make use of the database by determining whether they are at risk of experiencing adverse events.

Watson will also be able to continuously update itself with every new piece of information it processes. This information could help pharmaceutical developers avoid the costs associated with failed drugs, thereby allowing them to focus their efforts on more promising therapeutics.

Keywords: Drug Safety, Adverse Event, Clinical Trial


Share this with your colleagues!

IBS Patients Taking Viberzi May Be at Increased Risk of Pancreatitis

March 22, 2017 - According to a recent drug safety communication issued by the US Food and Drug Administration (FDA), patients with irritable bowel syndrome (IBS) with diarrhea should not be treated using Viberzi (eluxadoline), if they do not have a gallbladder.

Featured In: Drug Safety News

PTC to Acquire Marathon’s Recently Approved Duchenne Muscular Dystrophy Drug

March 17, 2017 - Amid a drug pricing controversy, PTC Therapeutics has agreed to buy Marathon Pharmaceuticals’ Duchenne muscular dystrophy (DMD) drug, Emflaza.

Featured In: Pharmaceutical News

Memphis Meats Produces World’s First Poultry from Animal Cells

March 17, 2017 - Silicon Valley-based food manufacturing company, Memphis Meats, has produced the world’s first “clean poultry” by growing chicken and duck cells outside the animals.

Featured In: Food News


Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?


How to Improve the Speed and Efficiency of Your Clinical Trials

High Performance Computing for High Content Screening - A Case Study

The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review

Treatment of Psoriasis: Improvements Through Clinical Trials

Copyright © 2016-2017 Honeycomb Worldwide Inc.